Replies to post #6291 on NorthWest Biotherapeutics Inc (NWBO)

[bbking2003]

Separately, DCVax-L was also cleared as eligible for reimbursement through German sickness funds (i.e., insurance companies), which prompted six hospitals to apply for reimbursement eligibility. This represents a solid first step in validating DCVax-L and should help generate revenue to offset some of its ongoing losses, but its phase 3 study of DCVax-L in the U.S. for glioblastoma multiforme, the most lethal form of brain cancer, should remain the focus of shareholders in the meantime.

[RollitUpPlease]

Thanks for the article BB. You always link the good stuff!